Impact of age and sex on survival outcomes in patients aged 1-45 years with acute lymphoblastic leukemia treated according to the stratification used in the NOPHO ALL2008 trial

Age and sex have historically been associated with differences in acute lymphoblastic leukemia (ALL) survival. In the NOPHO ALL2008 trial, patients aged 1-45 years with BCR::ABL1-negative B-precursor and Tcell ALL were included, but neither sex nor age was integrated into risk group allocation. Amo...

Full description

Saved in:
Bibliographic Details
Main Authors: Tuomas Lahteenmaki Taalas, Trausti Oskarsson, Mats Heyman, Bendik Lund, Kristi Lepik, Goda Vaitkevičiene, Olafur Gisli Jonsson, Julia Eriksson, Nina Toft, Laimonas Griškevičius, Helene Hallbook, Katrin Palk, Ulla Wartiovaara-Kautto, Petter Quist-Paulsen, Ulrika Noren-Nystrom, Kim Vettenranta, Jonas Abrahamsson, Kjeld Schmiegelow, Paivi M Lahteenmaki
Format: Article
Language:English
Published: Ferrata Storti Foundation 2025-02-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/11948
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850192303071690752
author Tuomas Lahteenmaki Taalas
Trausti Oskarsson
Mats Heyman
Bendik Lund
Kristi Lepik
Goda Vaitkevičiene
Olafur Gisli Jonsson
Julia Eriksson
Nina Toft
Laimonas Griškevičius
Helene Hallbook
Katrin Palk
Ulla Wartiovaara-Kautto
Petter Quist-Paulsen
Ulrika Noren-Nystrom
Kim Vettenranta
Jonas Abrahamsson
Kjeld Schmiegelow
Paivi M Lahteenmaki
author_facet Tuomas Lahteenmaki Taalas
Trausti Oskarsson
Mats Heyman
Bendik Lund
Kristi Lepik
Goda Vaitkevičiene
Olafur Gisli Jonsson
Julia Eriksson
Nina Toft
Laimonas Griškevičius
Helene Hallbook
Katrin Palk
Ulla Wartiovaara-Kautto
Petter Quist-Paulsen
Ulrika Noren-Nystrom
Kim Vettenranta
Jonas Abrahamsson
Kjeld Schmiegelow
Paivi M Lahteenmaki
author_sort Tuomas Lahteenmaki Taalas
collection DOAJ
description Age and sex have historically been associated with differences in acute lymphoblastic leukemia (ALL) survival. In the NOPHO ALL2008 trial, patients aged 1-45 years with BCR::ABL1-negative B-precursor and Tcell ALL were included, but neither sex nor age was integrated into risk group allocation. Among 1,771 trial patients stratified into protocol-appropriate risk groups, we estimated the impact of age and sex on survival (even after relapse) and toxicities prospectively registered at three-month intervals. In multivariate Cox regression analysis adjusted by sex, age group, and risk group, age but not sex was an independent risk factor for reduced 5-year event-free survival (EFS), hazard ratio 1.57 (95%CI 1.15-2.14) for patients 10-17.9 years, and 2.70 (2.03-3.58) for patients 18-45 years, compared to patients
format Article
id doaj-art-a092caad419c435a9e243a08512faef4
institution OA Journals
issn 0390-6078
1592-8721
language English
publishDate 2025-02-01
publisher Ferrata Storti Foundation
record_format Article
series Haematologica
spelling doaj-art-a092caad419c435a9e243a08512faef42025-08-20T02:14:37ZengFerrata Storti FoundationHaematologica0390-60781592-87212025-02-01999110.3324/haematol.2024.286043Impact of age and sex on survival outcomes in patients aged 1-45 years with acute lymphoblastic leukemia treated according to the stratification used in the NOPHO ALL2008 trialTuomas Lahteenmaki Taalas0Trausti Oskarsson1Mats Heyman2Bendik Lund3Kristi Lepik4Goda Vaitkevičiene5Olafur Gisli Jonsson6Julia Eriksson7Nina Toft8Laimonas Griškevičius9Helene Hallbook10Katrin Palk11Ulla Wartiovaara-Kautto12Petter Quist-Paulsen13Ulrika Noren-Nystrom14Kim Vettenranta15Jonas Abrahamsson16Kjeld Schmiegelow17Paivi M Lahteenmaki18Department of Pediatric and Adolescent Medicine, Turku University Hospital, FICAN-West, and Turku University, TurkuDepartment of Paediatric Oncology, Astrid Lindgren Children's Hospital, Stockholm, Sweden; Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, StockholmDepartment of Paediatric Oncology, Astrid Lindgren Children's Hospital, Stockholm, Sweden; Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, StockholmDepartment of Pediatrics, St. Olavs Hospital, TrondheimTallinn Children’s Hospital, Tallinn, EstoniaCentre for Pediatric Oncology and Hematology, Children’s Hospital, Affiliate of Vilnius University Hospital Santariskiu Klinikos, Vilnius, LithuaniaChildren's Hospital, Landspitali University Hospital, ReykjavikDivision of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, StockholmDepartment of Hematology, University Hospital Rigshospitalet, CopenhagenHematology, Oncology and Transfusion Medicine Center Vilnius University Hospital Santaros Klinikos, Vilnius University, Vilnius, LithuaniaDepartment of Medical Sciences, Uppsala University, UppsalaDepartment of Hematology, North Estonia Medical Centre, Tallinn, EstoniaDepartment of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, HelsinkiDepartment of Hematology, St. Olav’s Hospital, Trondheim University Hospital, TrondheimDepartment of Clinical Sciences, Pediatrics, Umea University, UmeaDivision of Pediatric Hematology-Oncology and Stem Cell Transplantation, Helsinki University Central Hospital, HelsinkiChildren’s Cancer Center, Department of Pediatrics, Sahlgrenska University Hospital, GoteborgDepartment of Pediatrics and Adolescent Medicine, Rishospitalet University Hospital and Institute of Clinical Medicine, Faculty of Medicine, University of CopenhagenDepartment of Pediatric and Adolescent Medicine, Turku University Hospital, FICAN-West, and Turku University, Turku, Finland; Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm Age and sex have historically been associated with differences in acute lymphoblastic leukemia (ALL) survival. In the NOPHO ALL2008 trial, patients aged 1-45 years with BCR::ABL1-negative B-precursor and Tcell ALL were included, but neither sex nor age was integrated into risk group allocation. Among 1,771 trial patients stratified into protocol-appropriate risk groups, we estimated the impact of age and sex on survival (even after relapse) and toxicities prospectively registered at three-month intervals. In multivariate Cox regression analysis adjusted by sex, age group, and risk group, age but not sex was an independent risk factor for reduced 5-year event-free survival (EFS), hazard ratio 1.57 (95%CI 1.15-2.14) for patients 10-17.9 years, and 2.70 (2.03-3.58) for patients 18-45 years, compared to patients https://haematologica.org/article/view/11948
spellingShingle Tuomas Lahteenmaki Taalas
Trausti Oskarsson
Mats Heyman
Bendik Lund
Kristi Lepik
Goda Vaitkevičiene
Olafur Gisli Jonsson
Julia Eriksson
Nina Toft
Laimonas Griškevičius
Helene Hallbook
Katrin Palk
Ulla Wartiovaara-Kautto
Petter Quist-Paulsen
Ulrika Noren-Nystrom
Kim Vettenranta
Jonas Abrahamsson
Kjeld Schmiegelow
Paivi M Lahteenmaki
Impact of age and sex on survival outcomes in patients aged 1-45 years with acute lymphoblastic leukemia treated according to the stratification used in the NOPHO ALL2008 trial
Haematologica
title Impact of age and sex on survival outcomes in patients aged 1-45 years with acute lymphoblastic leukemia treated according to the stratification used in the NOPHO ALL2008 trial
title_full Impact of age and sex on survival outcomes in patients aged 1-45 years with acute lymphoblastic leukemia treated according to the stratification used in the NOPHO ALL2008 trial
title_fullStr Impact of age and sex on survival outcomes in patients aged 1-45 years with acute lymphoblastic leukemia treated according to the stratification used in the NOPHO ALL2008 trial
title_full_unstemmed Impact of age and sex on survival outcomes in patients aged 1-45 years with acute lymphoblastic leukemia treated according to the stratification used in the NOPHO ALL2008 trial
title_short Impact of age and sex on survival outcomes in patients aged 1-45 years with acute lymphoblastic leukemia treated according to the stratification used in the NOPHO ALL2008 trial
title_sort impact of age and sex on survival outcomes in patients aged 1 45 years with acute lymphoblastic leukemia treated according to the stratification used in the nopho all2008 trial
url https://haematologica.org/article/view/11948
work_keys_str_mv AT tuomaslahteenmakitaalas impactofageandsexonsurvivaloutcomesinpatientsaged145yearswithacutelymphoblasticleukemiatreatedaccordingtothestratificationusedinthenophoall2008trial
AT traustioskarsson impactofageandsexonsurvivaloutcomesinpatientsaged145yearswithacutelymphoblasticleukemiatreatedaccordingtothestratificationusedinthenophoall2008trial
AT matsheyman impactofageandsexonsurvivaloutcomesinpatientsaged145yearswithacutelymphoblasticleukemiatreatedaccordingtothestratificationusedinthenophoall2008trial
AT bendiklund impactofageandsexonsurvivaloutcomesinpatientsaged145yearswithacutelymphoblasticleukemiatreatedaccordingtothestratificationusedinthenophoall2008trial
AT kristilepik impactofageandsexonsurvivaloutcomesinpatientsaged145yearswithacutelymphoblasticleukemiatreatedaccordingtothestratificationusedinthenophoall2008trial
AT godavaitkeviciene impactofageandsexonsurvivaloutcomesinpatientsaged145yearswithacutelymphoblasticleukemiatreatedaccordingtothestratificationusedinthenophoall2008trial
AT olafurgislijonsson impactofageandsexonsurvivaloutcomesinpatientsaged145yearswithacutelymphoblasticleukemiatreatedaccordingtothestratificationusedinthenophoall2008trial
AT juliaeriksson impactofageandsexonsurvivaloutcomesinpatientsaged145yearswithacutelymphoblasticleukemiatreatedaccordingtothestratificationusedinthenophoall2008trial
AT ninatoft impactofageandsexonsurvivaloutcomesinpatientsaged145yearswithacutelymphoblasticleukemiatreatedaccordingtothestratificationusedinthenophoall2008trial
AT laimonasgriskevicius impactofageandsexonsurvivaloutcomesinpatientsaged145yearswithacutelymphoblasticleukemiatreatedaccordingtothestratificationusedinthenophoall2008trial
AT helenehallbook impactofageandsexonsurvivaloutcomesinpatientsaged145yearswithacutelymphoblasticleukemiatreatedaccordingtothestratificationusedinthenophoall2008trial
AT katrinpalk impactofageandsexonsurvivaloutcomesinpatientsaged145yearswithacutelymphoblasticleukemiatreatedaccordingtothestratificationusedinthenophoall2008trial
AT ullawartiovaarakautto impactofageandsexonsurvivaloutcomesinpatientsaged145yearswithacutelymphoblasticleukemiatreatedaccordingtothestratificationusedinthenophoall2008trial
AT petterquistpaulsen impactofageandsexonsurvivaloutcomesinpatientsaged145yearswithacutelymphoblasticleukemiatreatedaccordingtothestratificationusedinthenophoall2008trial
AT ulrikanorennystrom impactofageandsexonsurvivaloutcomesinpatientsaged145yearswithacutelymphoblasticleukemiatreatedaccordingtothestratificationusedinthenophoall2008trial
AT kimvettenranta impactofageandsexonsurvivaloutcomesinpatientsaged145yearswithacutelymphoblasticleukemiatreatedaccordingtothestratificationusedinthenophoall2008trial
AT jonasabrahamsson impactofageandsexonsurvivaloutcomesinpatientsaged145yearswithacutelymphoblasticleukemiatreatedaccordingtothestratificationusedinthenophoall2008trial
AT kjeldschmiegelow impactofageandsexonsurvivaloutcomesinpatientsaged145yearswithacutelymphoblasticleukemiatreatedaccordingtothestratificationusedinthenophoall2008trial
AT paivimlahteenmaki impactofageandsexonsurvivaloutcomesinpatientsaged145yearswithacutelymphoblasticleukemiatreatedaccordingtothestratificationusedinthenophoall2008trial